Scarica l'app Stockscreener
93.19
3.63%
3.26
Dopo l'orario di chiusura:
93.19
Precedente Chiudi:
$89.93
Aprire:
$91.16
Volume 24 ore:
1.24M
Relative Volume:
1.08
Capitalizzazione di mercato:
$8.22B
Reddito:
$688.00K
Utile/perdita netta:
$-168.74M
Rapporto P/E:
-39.53
EPS:
-2.3577
Flusso di cassa netto:
$-185.87M
1 W Prestazione:
+8.75%
1M Prestazione:
+7.05%
6M Prestazione:
+95.86%
1 anno Prestazione:
+483.17%
Intervallo 1D:
$90.48
$95.27
Intervallo di 1 settimana:
$83.25
$95.27
Portata 52W:
$15.86
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
93.19 | 7.56B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Raymond James | Strong Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
45,000 shares are proposed for sale at Spyre Therapeutics (SYRE), following two earlier sales. - Stock Titan
A passive investor reports more than 5% ownership of Spyre Therapeutics (SYRE). - Stock Titan
Spyre draws new Overweight at J.P. Morgan on IBD potential - Seeking Alpha
SYRE Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Why is Spyre Therapeutics stock climbing today? By Investing.com - Investing.com Canada
JPMorgan initiates Spyre stock with Overweight on IBD pipeline - Investing.com
Spyre Therapeutics gains as investors continue to digest positive Phase 2 bowel disease data - Quiver Quantitative
A 17,500-share sale is proposed by Spyre Therapeutics (Nasdaq: SYRE) officer Scott Burrows. - Stock Titan
SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline - StocksToTrade
SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations - timothysykes.com
Why is Spyre Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Spyre Therapeuticsの社内関係者が保有株を28%削減 - Moomoo
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121 - Moomoo
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Cameron Turtle: The $1.6 Billion Bet That IBD's 25% Ceiling Is About to Break - finance.biggo.com
Spyre Therapeutics at Stifel forum: betting on autoimmune combinations By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history - Yahoo Finance Australia
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis? - Yahoo Finance
Spyre Therapeutics, Inc Income Statement – MUN:3920 - TradingView
Equity in earnings of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Total liabilities of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: A Biotech Stock with a Potential 29.56% Upside - DirectorsTalk Interviews
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests - Yahoo Finance
Spyre Therapeutics, Inc Statistics – GETTEX:3920 - TradingView
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - investing.com
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spyre Therapeutics Inc Azioni (SYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| King-Jones Heidy | See Remarks |
Sep 02 '26 |
Option Exercise |
14.50 |
400 |
5,800 |
3,245 |
| King-Jones Heidy | See Remarks |
Sep 01 '26 |
Sale |
87.31 |
27,999 |
2,444,529 |
2,845 |
| King-Jones Heidy | See Remarks |
Sep 02 '26 |
Sale |
90.00 |
400 |
36,000 |
2,845 |
| Burrows Scott L | Chief Financial Officer |
Sep 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
105,494 |
| Burrows Scott L | Chief Financial Officer |
Sep 02 '26 |
Sale |
89.35 |
18,232 |
1,629,029 |
79,762 |
| Burrows Scott L | Chief Financial Officer |
Sep 01 '26 |
Sale |
87.31 |
7,500 |
654,792 |
97,994 |
| Turtle Cameron | Chief Executive Officer |
Sep 01 '26 |
Sale |
87.29 |
15,000 |
1,309,410 |
552,540 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):